MarketInOut Stock Screener Log In | Sign Up

Alvotech Wt

NASDAQ • Healthcare • Drug Manufacturers - Specialty & Generic • Quote as of 11/13/2026
Alvotech Wt stock price and volume chart

Company Profile

IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,856.72 mln
Float141 mln
Earnings Date11/11/2026

Piotroski F-Score

2 / 9
Weak

Beneish M-Score

-2.47
Borderline

Relative Strength

63 / 100
Outperforming

Pre-Tax Margin

-23%
Deeply loss-making

ROE

76.83
Exceptional

Altman Z-Score

-0.96
Deeply distressed

Business Description

Founded in 2013 and headquartered in Luxembourg, Alvotech develops and manufactures biosimilar medicines designed to offer more accessible alternatives to established biologic treatments. The company's portfolio spans a wide range of conditions, including inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis, as well as eye conditions, bone-related complications from cancer, allergic asthma, and certain cancers. Its products are built to closely replicate some of the world's best-known biologic drugs, including Humira, Stelara, Eylea, and Keytruda, among others. Alvotech serves patients across global markets through its growing pipeline of approved and in-development biosimilar treatments.

Key Fundamentals

EPS-0.58
ROE76.83
RPS1.67
ROIC4.35
ROA-16.57
Interest Cover0.27
EBITDA, mln75.73
EV / EBITDA429
Revenue, mln495

Quote Details

Last 0.20
Change 0.0596 (42.45%)
Open 0.2753
Volume 2,210
Turnover 442
Average Volume 4,598.19

Financial Ratios

Pre-Tax Profit Margin-23
Current Ratio1.78
Price / Sales4.51

Financial Strength

Altman Z-Score-0.96
Piotroski F-Score 2 / 9
Beneish M-Score-2.47

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 33.24% 99 / 100   
1 Month -38.89% 7 / 100   
2 Months -9.09% 39 / 100   
6 Months -76.59% 6 / 100   
1 Year -88.89% 6 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog